The TAK-881-3001 clinical trial evaluated the PK, efficacy, safety, tolerability and immunogenicity of TAK-881 in adults and pediatric patients aged 2 years and older with PID previously treated with ...
A pivotal study of a Takeda primary immunodeficiency disease (PID) asset has hit its primary endpoint, demonstrating ...
November 14, 2011 — Recurrent pelvic inflammatory disease (PID) is associated with an increased risk for infertility and chronic pelvic pain (CPP), according to a study published in the September ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results